Show simple item record

dc.contributor.authorMacDowell, Karina S.
dc.contributor.authorMunarriz Cuezva, Eva
dc.contributor.authorMeana Martínez, José Javier ORCID
dc.contributor.authorLeza, Juan Carlos
dc.contributor.authorOrtega Calvo, Jorge
dc.date.accessioned2021-06-25T07:57:58Z
dc.date.available2021-06-25T07:57:58Z
dc.date.issued2021-05-13
dc.identifier.citationFrontiers in Pharmacology 12 : (2021) // Article ID 682602es_ES
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/10810/52012
dc.description.abstractEmerging evidence indicates that early-life exposure to environmental factors may increase the risk for schizophrenia via inflammatory mechanisms. Inflammation can alter the metabolism of tryptophan through the oxidative kynurenine pathway to compounds with neurotoxic and neuroprotective activity and compromise serotonin (5-HT) synthesis. Here we investigate the role of serotonergic and kynurenine pathways in the maternal immune activation (MIA) animal model of schizophrenia. The potential reversion exerted by long-term antipsychotic treatment was also evaluated. MIA was induced by prenatal administration of polyinosinic:polycytidylic acid (poly (I:C)) in mice. Expression of different proteins and the content of different metabolites involved in the function of serotonergic and kynurenine pathways was assessed by RT-PCR, immunoblot and ELISA analyses in frontal cortex of the offspring after puberty. MIA decreased tissue 5-HT content and promoted changes in the expression of serotonin transporter, 5-HT2A and 5-HT2C receptors. Expression of indoleamine 2,3-dioxygenase 2 (IDO2) and kynurenine 3-monooxygenase (KMO) was increased by poly (I:C) whereas kynurenine aminotransferase II and its metabolite kynurenic acid were not altered. Long-term paliperidone was able to counteract MIA-induced changes in 5-HT and KMO, and to increase tryptophan availability and tryptophan hydroxylase-2 expression in poly (I:C) mice but not in controls. MIA-induced increase of the cytotoxic risk ratio of kynurenine metabolites (quinolinic/kynurenic acid) was also reversed by paliperidone. MIA induces specific long-term brain effects on serotonergic activity. Such effects seem to be related with alternative activation of the kynurenine metabolic pathway towards a cytotoxic status. Atypical antipsychotic paliperodine partially remediates abnormalities observed after MIA.es_ES
dc.description.sponsorshipThis work was supported by MINECO-FEDER Funds (SAF201675500-R to JL; SAF2017-88126-R to JM); Centro de Investigacion en Red de Salud Mental, CIBERSAM; and the Basque Government (IT1211-19). Editoriales_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF201675500-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2017-88126-Res_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectschizophreniaes_ES
dc.subjectatypical antipsychoticses_ES
dc.subjectkynureninees_ES
dc.subjectserotonines_ES
dc.subjectmaternal immune activationes_ES
dc.subjectpolyinosinices_ES
dc.subjectpolycytidylic acid (poly(I; C))es_ES
dc.subjectschizophrenia-like alterationses_ES
dc.subjectprenatal immunees_ES
dc.subjectneurodevelopmental modeles_ES
dc.subjectdopaminergic hyperfunctiones_ES
dc.subjecttryptophan depletiones_ES
dc.subjectcytokine alterationses_ES
dc.subjectcognitive deficitses_ES
dc.subject1st episodees_ES
dc.subjectmouse modeles_ES
dc.subjectinflammationes_ES
dc.titlePaliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathwayses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder2021 MacDowell, Munarriz-Cuezva, Meana, Leza and Ortega. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fphar.2021.682602/fulles_ES
dc.identifier.doi10.3389/fphar.2021.682602
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

2021 MacDowell, Munarriz-Cuezva, Meana, Leza and Ortega. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as 2021 MacDowell, Munarriz-Cuezva, Meana, Leza and Ortega. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.